This report describes the successful treatment of an immunsupressed host suffering from severe aspergillus osteomyelitis and tuberculosis co-infection, using liposomal amphotericin B.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Fungal organisms are increasingly recognized as serious and potentially fatal pathogens in the immunosuppressed host.
📊
Key Findings & Data:There is a critical need for alternatives to amphotericin B as a treatment for such life-threatening fungal infections as invasive aspergillosis; because although amphotericin B is used to treat fungal infections that are resistant to other antifungal drugs, such as fluconazole and ketoconazole, there are severe toxic effects of amphotericin B include fever, chills, muscle pain, phlebitis, vomiting, potassium loss, kidney dysfunctions and anemia.
💡
Conclusion & Impact:This report describes the successful treatment of an immunsupressed host suffering from severe aspergillus osteomyelitis and tuberculosis co-infection, using liposomal amphotericin B.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Fungal organisms are increasingly recognized as serious and potentially fatal pathogens in the immunosuppressed host. There is a critical need for alternatives to amphotericin B as a treatment for such life-threatening fungal infections as invasive aspergillosis; because although amphotericin B is used to treat fungal infections that are resistant to other antifungal drugs, such as fluconazole and ketoconazole, there are severe toxic effects of amphotericin B include fever, chills, muscle pain, phlebitis, vomiting, potassium loss, kidney dysfunctions and anemia. Liposomal bounded amphotericin B also shows a distinctly lower toxic profile, even in higher concentrations in the plasma, than conventional amphotericin B. This report describes the successful treatment of an immunsupressed host suffering from severe aspergillus osteomyelitis and tuberculosis co-infection, using liposomal amphotericin B.
🔖
Cite This Article
ERGÜVEN, M., ÖZÜMÜZTOPRAK, N., SAÇAR, O. (2022). Using liposomal amphotericin B at aspergillus osteomyelitis. Göztepe Tıp Dergisi, Cilt: 18 - Sayı: 3, 191–192. https://ajindex.com/articles/526485
Denning DW, Stevens DA: Antifungal and surgical treatment, of invasive aspergillosis; review of 2121 published cases. Rev. of Inf. Diseases 12:1147-1201,1990
Smart T: Liposonial Amphotericin B enters U.S. trials. Gay Men's Heallti Crisis; Treatment Issues, Vol. 8, No. 3, May 1994
Ellis M, Spence D, et al: An EORTC International Multicentcr Randomized Trial (EORTC Number 19923) comparing two dosages of Liposonial Amphotericin B for treatment of invasive aspergillosis. Clin. Inf. Diseases 27:1406-12,1998
Mills W, Chopra R, Linen DC, Goldstone AH: Uposomai Amphotericin B in the treatment of fungal infections in neuropenic patients: A single center experience of 133 episodes in 116 cases. Br J Haemotology 86:754-760,1994
Walsh TJ, Fohn W, Hiemenz JW, et al: Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 566 cases. Clin Inf Diseases 26:1383-96,1998
Sievers R, Neubaucr AP, Natzschka J: Therapie mit lipozomalem Amphotericin B bei neonataler Pilzscpsis mit enzephalitischer und osteoaitritis-cher Beteiligung. Montssch Kinderheilkunde 142:266-68, 1994
Wingard JR, Kubilis P, Lee L, Lee G, et al: Clinical significance of nefro-toxicity in patients wilh Amphotericine B for suspected or proven aspergillosis. Clin Inf Dis 29:1402-1407.1999
Patterson TF, Miniter F, Ryan JL, Andriole VT: Effect of immunosup-pression and Amphotericin B on aspergillosis antigenemia in an experimental model. J Inf Dis 158:415-22,1998
Walsh TJ, Finberg RW, et al:Liposomal Amphotericin B for empirical therapy in patients with persistent fever and neutropenia The England Journal of Medicine 340:764-77,1999
Prentice HG, Hann IM, Herbrecht R, et al: A randomized comparision of Lipozomal versus convential Amphotericin B for the treatment of pyrcxia of unknown origin in neutropenic patients. Br J Haemotol 98:711 -8,1998
Gallis HA, Drew RH, Pickard WW: Amphotericin B: 30 years of clinical experience. Rev Inf Dis 12:308-29,1990
Mehta T, Lopez-Bernstein G, Hopfer R, et al: Liposomal Amphotericin B is toxic to fungal cells but not to mammalian cells. Biocbemia et Biophysiai Acta 770:230-234,1984
Olsen SJ, Swerdel MR, Blue B, et al: Tissue distribution of Amphotericin B lipid komplex in laboratory animals. J Pharm 43:831-5,1991
Janoff AS, Bom LT, et al: Unusual lipid structures selectively reduce the toxicity of Amphotericin B.Proc Natl Acad Set USA 85:6122-6,1998